InflaRx N.V. (IFRX)
IFRXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$1.21
-0.1000 (-7.63%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $178.32m
- P/E
- –
- EPS, last 4 quarters
- $-0.3900
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.7984 to $2.95
- Average volume
- 761.2k
- Previous close
- $1.31
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $8.00, +561.2% from here
Earnings
next estimate $-0.0500Next report
Dec 2025
+5.6%
Mar 2026
+47.1%
Jun 2026
-37.5%
Sep 2026
+71.4%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- InflaRx Publishes First-In-Human Phase 1 Results For Izicopan; Stock Up RTTNews · 1 day ago
- InflaRx N.V. Announces Publication of Phase 1 Data for IzicopanFintel · 4 days ago
- InflaRx Highlights Positive Phase 1 Findings For Oral Drug Candidate Izicopan; Stock Down RTTNews · 5 days ago
- InflaRx N.V. Reports €18.7 million Net Loss for the Nine Months Ended September 30, 2026Fintel · Nov 3, 2026
- InflaRx Outlines Izicopan Development Plans In Vasculitis; Targets $2 Bln Peak Sales RTTNews · Nov 3, 2026
- InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan TrialsMarketBeat · Nov 3, 2026
- InflaRx N.V. Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026Fintel · Oct 22, 2026
- Needham Initiates Coverage of InflaRx N.V. with Buy RatingFintel · Sep 14, 2026
The company
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx's lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- inflarx.de
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.